Home > In process > Chrysoeriol-Mediated Neuroprotection in Parkinson's Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery. > print

001     285814
005     20260401151453.0
024 7 _ |a 10.59249/CTWM1697
|2 doi
024 7 _ |a pmid:41918512
|2 pmid
024 7 _ |a pmc:PMC13023422
|2 pmc
024 7 _ |a 0044-0086
|2 ISSN
024 7 _ |a 1551-4056
|2 ISSN
037 _ _ |a DZNE-2026-00350
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ali, Mehak
|b 0
245 _ _ |a Chrysoeriol-Mediated Neuroprotection in Parkinson's Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery.
260 _ _ |a New Haven, Conn.
|c 2026
|b [Verlag nicht ermittelbar]
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1775049203_19920
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Parkinson's disease (PD) is a neurodegenerative disorder marked by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to significant motor dysfunction. Current treatments stabilize dopamine levels but fail to address underlying neuronal apoptosis, highlighting the need for novel approaches. Although chrysoeriol, a 3'-O-methoxy flavone and luteolin derivative, is well-documented for its anti-cancer, anti-diabetic, antioxidant, and anti-inflammatory properties, its neuroprotective potential in PD, particularly in vivo, remains largely unexplored. This study fills a critical gap by being the first to systematically assess chrysoeriol's neuroprotective effects in a PD mouse model. We evaluated the effects of 5 mg/kg chrysoeriol administered intraperitoneally (IP) for 14 days in an acute 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model. Behavioral tests showed notable recovery, as chrysoeriol eliminated deficits in motor function, coordination, and balance, as assessed by the pole test, forced swim test, and tail suspension test. It also mitigated exploratory and locomotor deficits in the open field test, and the Y-maze test revealed improved spatial and learning memory. Hematoxylin and eosin staining indicated a significant reduction in neuronal damage across key brain regions. qPCR analysis showed reduced 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity, downregulation of α-synuclein, and an improved Bcl-2/Bax ratio. These findings suggest chrysoeriol may protect against MPP+-induced apoptosis in mice, potentially via the PI3K/Akt signaling pathway, and reduces mitochondrial damage by downregulating α-synuclein.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a BAX
|2 Other
650 _ 7 |a Bcl-2
|2 Other
650 _ 7 |a Neuroprotective
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a chrysoeriol
|2 Other
650 _ 7 |a α-Synuclein
|2 Other
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 7 |a Neuroprotective Agents
|2 NLM Chemicals
650 _ 7 |a Flavones
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Apoptosis: drug effects
|2 MeSH
650 _ 2 |a alpha-Synuclein: metabolism
|2 MeSH
650 _ 2 |a Neuroprotective Agents: pharmacology
|2 MeSH
650 _ 2 |a Neuroprotective Agents: therapeutic use
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Parkinson Disease: drug therapy
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Recovery of Function: drug effects
|2 MeSH
650 _ 2 |a Flavones: pharmacology
|2 MeSH
650 _ 2 |a Neuroprotection: drug effects
|2 MeSH
650 _ 2 |a Dopaminergic Neurons: drug effects
|2 MeSH
650 _ 2 |a Dopaminergic Neurons: metabolism
|2 MeSH
700 1 _ |a Mehreen, Mehwish
|b 1
700 1 _ |a Batool, Saima
|b 2
700 1 _ |a Khan, Shahrukh
|b 3
700 1 _ |a Noor, Aneeqa
|b 4
700 1 _ |a Mumtaz, Sara
|b 5
700 1 _ |a Zafar, Saima
|0 P:(DE-2719)9000358
|b 6
|e Last author
|u dzne
773 _ _ |a 10.59249/CTWM1697
|g Vol. 99, no. 1, p. 111 - 126
|0 PERI:(DE-600)2063545-X
|n 1
|p 111 - 126
|t Yale journal of biology and medicine
|v 99
|y 2026
|x 0044-0086
856 4 _ |u https://pub.dzne.de/record/285814/files/DZNE-2026-00350.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285814/files/DZNE-2026-00350.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000358
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b YALE J BIOL MED : 2022
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-02-19T11:40:40Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-02-19T11:40:40Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review, Double anonymous peer review
|d 2024-02-19T11:40:40Z
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version)
|0 LIC:(DE-HGF)CCBYNCNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-02-19T11:40:40Z
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-11-12
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarker
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1440011-1
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21